Literature DB >> 18780835

Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection.

Alberto Cagigi1, Frida Mowafi, Linh V Phuong Dang, Klara Tenner-Racz, Ann Atlas, Sven Grutzmeier, Paul Racz, Francesca Chiodi, Anna Nilsson.   

Abstract

HIV-1 infection is associated with B-cell abnormalities, such as hypergammaglobulinemia, poor immunization responses, and loss of serologic memory. To determine whether altered expression of chemokine receptors and their ligands may play a role in B-cell dysfunctions during HIV-1 infection, the expression of CXC chemokine receptor 4 (CXCR4), CXCR5, and CC chemokine receptor 7 (CCR7) and their respective ligands on CD19(+) B cells were examined in HIV-1-infected patients and controls. We report a decreased CXCR5 expression on B cells from patients (P < .05), a phenomenon associated with a low CD4 T-cell count (< 350 cells/microL). Interestingly, an increased expression of CXC chemokine ligand 13 (CXCL13), the ligand for CXCR5, was found in peripheral B cells from HIV-1-infected patients. Moreover, on B-cell activation in vitro, CXCL13 was secreted in culture. CXCL13(+) B cells were also found in the lymph nodes of HIV-1-infected patients, but not in control tissue. B-cell migration toward CXCL13, CXCL12, and CC chemokine ligand 21 (CCL21), ligands for CXCR5, CXCR4, and CCR7 was also evaluated. In patients with a low CD4 T-cell count, migration toward all ligands was increased. Our findings indicate that altered expression of the chemokine receptor-ligand pair, CXCR5/CXCL13, may participate in the establishment of B-cell dysfunctions during HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18780835     DOI: 10.1182/blood-2008-02-140426

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN.

Authors:  Kristen W Cohen; Anne-Sophie Dugast; Galit Alter; M Juliana McElrath; Leonidas Stamatatos
Journal:  J Immunol       Date:  2015-02-09       Impact factor: 5.422

2.  New therapy to revert dysfunctional antibody responses during HIV-1 infection.

Authors:  Francesca Chiodi
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

3.  Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid.

Authors:  N D van Burgel; F Bakels; A C M Kroes; A P van Dam
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

4.  MicroRNA-125-5p targeted CXCL13: a potential biomarker associated with immune thrombocytopenia.

Authors:  Jian-Qin Li; Shao-Yan Hu; Zhao-Yue Wang; Jing Lin; Su Jian; Yong-Chao Dong; Xiao-Fang Wu; Dai Lan; Li-Juan Cao
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

Review 5.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

6.  Macaque paneth cells express lymphoid chemokine CXCL13 and other antimicrobial peptides not previously described as expressed in intestinal crypts.

Authors:  Carissa M Lucero; Beth Fallert Junecko; Cynthia R Klamar; Lauren A Sciullo; Stella J Berendam; Anthony R Cillo; Shulin Qin; Yongjun Sui; Sonali Sanghavi; Michael A Murphey-Corb; Todd A Reinhart
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

7.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

8.  Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk.

Authors:  Shehnaz K Hussain; Weiming Zhu; Shen-Chih Chang; Elizabeth Crabb Breen; Elena Vendrame; Larry Magpantay; Dan Widney; Daniel Conn; Mary Sehl; Lisa P Jacobson; Jay H Bream; Steven Wolinsky; Charles R Rinaldo; Richard F Ambinder; Roger Detels; Zuo-Feng Zhang; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-18       Impact factor: 4.254

Review 9.  Role of IL-21 and IL-21 receptor on B cells in HIV infection.

Authors:  Suresh Pallikkuth; Anita Parmigiani; Savita Pahwa
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

10.  Diminished CXCR5 expression in peripheral blood of patients with Sjögren's syndrome may relate to both genotype and salivary gland homing.

Authors:  L A Aqrawi; M Ivanchenko; A Björk; J I Ramírez Sepúlveda; J Imgenberg-Kreuz; M Kvarnström; P Haselmayer; J L Jensen; G Nordmark; K Chemin; K Skarstein; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2018-03-24       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.